Top Tweets for #Gejc
1L HER2-neg gastric/GEJC isn’t one bucket.
Biology splits into CLDN18.2 (targeted), CPS (IO), and dual-precision (CLDN18.2+PD-1).
ILUSTRO triplet shows the strongest signal in CLDN18.2-high.
#GastricCancer #GEJC #CLDN18 #PD1 #IO #ASCOGI #PrecisionOncology
ILUSTRO shows that dual-precision (CLDN18.2 + PD-1) may deepen 1L benefit in HER2-neg gastric/GEJC, especially in CLDN18.2-high. Phase 3 LUCERNA will test if it becomes a standard.
#GastricCancer #GEJC #CLDN18 #PD1 #IO #PrecisionOncology #ASCOGI #Oncology #ClinicalTrials
WELCOME To #ESMO25: The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER:
ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur
@acampsmalea
@BRicciutiMD
@yekeduz_emre
@HHorinouchi
@FadiHaddad_MD
@Abdallah81MD
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@bavilima
@realbowtiedoc
@Erman_Akkus
@Lucarecco
@GaiaGriguolo
@JankovicK
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@OscarTahuahua
@UOzkerim
@DrRishabhOnco
@Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi
@CathyEngMD
@marklewismd
@manjuggm
@stacy_hurt
@ARosen380
@KoheiShitara
@GillSharlene
@BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer See less
🔥 The @OncoAlert #GICancer Faculty proudly presents the🔝 🔟 #ESMO25 abstracts in #CRC, #HCC & #GEJC #ColonCancer
Get ready for the most exciting #GICancer 🆙dates coming from Berlin 🇩🇪! 😊
The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER: ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer
The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER: ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer
First trial of CAR-T cell cancer treatment for solid tumor response - @ShandaBlackmon
https://t.co/N64rsXeYrx
#ASCO2025 #Cancer #CARTCellTreatment #GEJC #MedEd #MedX #OncoDaily #Oncology #Satricabtagene #Autoleucel
Discover how to implement molecular testing and #immunotherapy in #GastricCancer and #GEJC through real-world scenarios and case-based learning. https://t.co/gZUmviKyuH
Exciting advancements in #GastricCancer and #GEJC treatment! Hear expert guidance from Samuel Cytryn, MD, and Yelena Y. Janjigian, MD, on how molecular testing and #immunotherapy are reshaping care standards. Watch today to earn CME/MOC/AAPA/IPCE credit https://t.co/gZUmviKyuH
#News for #Investors and #Media: We’re proud to be presenting important new data at #ESMOGI2024 from two of our Phase 3 studies in esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer. #ESCC #GEJC
Our @giconnectInfo expert Dr. David Tougeron will present a poster at #ASCO2022! Phase-II study evaluating #FOLFIRI + #durvalumab and #FOLFIRI + #durvalumab + #tremelimumab in advanced #GC or #GEJC: #PRODIGE59-DURIGAST. 4th June 14:00 BST Poster 24!
https://t.co/4r5TRLOrZo
#MedEd
Our @giconnectInfo expert Dr. David Tougeron will present a poster at #ASCO2022! Phase-II study evaluating #FOLFIRI + #durvalumab and #FOLFIRI + #durvalumab + #tremelimumab in advanced #GC or #GEJC: #PRODIGE59-DURIGAST. 4th June 14:00 BST Poster 24!
https://t.co/3azkuv06qF
#MedEd
Data from the #ATTRACTION-4 study is available! Effects of #nivolumab in combination with #chemotherapy compared to placebo with #chemotherapy in HER2 -ve unresectable/recurrent #gastriccancer or #GEJC!
https://t.co/kYTSD1V4DB
#MedEd #GC #GEJC
@Yelito80419129 ...te Jelito ale kto to wszystko organizuje..?...moze wiesz bystrzaku...no i jeszcze po co..Żydzi odpadają w szurskich opowiesciach to kto.. #Reptilians #bigFarma #Gejc ..zaznacz własciwe.
Just 3 days until #ESMO21! @YJanjigianMD will present a late breaking abstract on #nivolumab + #chemotherapy vs. #ipilimumab + chemotherapy as #First-line treatment in #GC #GEJC and #EAC, results from the #CheckMate649 study! LBA7 19/09 https://t.co/0JoWWP8iqU
#MedEd @myESMO
@DocCatenacci on phase III JAVELIN Gastric 100 switch maintenance with #IO is not #SOC in metastatic #GEJC/GC but highlights the yin-yang effect of #OS curves w/IOs, can we accentuate the yang portion of the curve w/further enrichment by PD-L1? @CSCancerCare @Dan_Theodorescu
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.8M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.9M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.3M followers
Virat Kohli
@imvkohli
70.3M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63.1M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61M followers
X
@x
60.8M followers